Endo Reiterates US Generics Environment Is ‘Challenging’
Follows Recent Comments By Sandoz And Teva
Endo’s non-injectable Generics revenues plunged by 28% in Q1, in part due to competitive challenges in the US generics sector that management said would continue through 2021.
